December 20, 2024 5:26 PM
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value. The lower-than-e...